Resistance to AFN-1252 arises from missense mutations in staphylococcus aureus Enoyl-Acyl carrier protein reductase (Fab1)

Journal of Biological Chemistry

Volumn 288, Issue 51, 2013, Pages 36261-36271

  Yao, Jiangwei ^a   Maxwell, John B ^a   Rock, Charles O ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC THERAPY; CARRIER PROTEINS; DRUG CONCENTRATION; STAPHYLOCOCCUS AUREUS;

DRUG THERAPY;

BACTERIA;

AFN 1252; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; FATTY ACID; HYDROXYL GROUP; METHIONINE; PROTEIN FABI; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRICLOSAN; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; COMPLEX FORMATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME MECHANISM; FABI GENE; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STAPHYLOCOCCUS AUREUS;

ACYL CARRIER PROTEIN; ANTIBIOTIC RESISTANCE; ANTIBIOTICS ACTION; DRUG RESISTANCE; ENOYL-ACP REDUCTASE; FABI; FATTY ACID SYNTHASE; STAPHYLOCOCCUS AUREUS;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BENZOFURANS; BINDING SITES; DRUG RESISTANCE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PROTEIN STRUCTURE, TERTIARY; PYRONES; STAPHYLOCOCCUS AUREUS;

EID: 84890919902     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.512905     Document Type: Article

References (47)

1. Rock, C. O., and Jackowski, S. (2002) Forty years of fatty acid biosynthesis. Biochem. Biophys. Res. Commun. 292, 1155-1166
2. Heath, R. J., and Rock, C. O. (1995) Enoyl-Acyl carrier protein reductase (fab1) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J. Biol. Chem. 270, 26538-26542
3. Heath, R. J., Rubin, J. R., Holland, D. R., Zhang, E., Snow, M. E., and Rock, C. O. (1999) Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 274, 11110-11114
4. Levy, C. W., Roujeinikova, A., Sedelnikova, S., Baker, P. J., Stuitje, A. R., Slabas, A. R., Rice, D. W., and Rafferty, J. B. (1999) Molecular basis of triclosan activity. Nature 398, 383-384
5. Heath, R. J., Su, N., Murphy, C. K., and Rock, C. O. (2000) The enoyl-[acylcarrier-protein] reductases Fab1 and FabL from Bacillus subtilis. J. Biol. Chem. 275, 40128-40133
6. Heath, R. J., Li, J., Roland, G. E., and Rock, C. O. (2000) Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-Acyl carrier protein reductase by triclosan and hexachlorophene. J. Biol. Chem. 275, 4654-4659
7. Lu, H., England, K., am Ende, C., Truglio, J. J., Luckner, S., Reddy, B. G., Marlenee, N. L., Knudson, S. E., Knudson, D. L., Bowen, R. A., Kisker, C., Slayden, R. A., and Tonge, P. J. (2009) Slow-onset inhibition of the Fab1 enoyl reductase from Francisella tularensis. Residence time and in vivo activity. ACS Chem. Biol. 4, 221-231
8. Parikh, S., Moynihan, D. P., Xiao, G., and Tonge, P. J. (1999) Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl- ACP reductase from Mycobacterium tuberculosis. Biochemistry 38, 13623-13634
9. Xu, H., Sullivan, T. J., Sekiguchi, J., Kirikae, T., Ojima, I., Stratton, C. F., Mao, W., Rock, F. L., Alley, M. R., Johnson, F., Walker, S. G., and Tonge, P. J. (2008) Mechanism and inhibition of saFab1, the enoyl reductase from Staphylococcus aureus. Biochemistry 47, 4228-4236
10. Stewart, M. J., Parikh, S., Xiao, G., Tonge, P. J., and Kisker, C. (1999) Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Mol. Biol. 290, 859-865
11. Schiebel, J., Chang, A., Lu, H., Baxter, M. V., Tonge, P. J., and Kisker, C. (2012) Staphylococcus aureus Fab1. Inhibition, substrate recognition, and potential implications for in vivo essentiality. Structure 20, 802-813
12. Chang, A., Schiebel, J., Yu, W., Bommineni, G. R., Pan, P., Baxter, M. V., Khanna, A., Sotriffer, C. A., Kisker, C., and Tonge, P. J. (2013) Rational optimization of drug-target residence time. Insights from inhibitor binding to the S. aureus Fab1 enzyme-product complex. Biochemistry 52, 4217-4228
13. Park, H. S., Yoon, Y. M., Jung, S. J., Kim, C. M., Kim, J. M., and Kwak, J. H. (2007) Antistaphylococcal activities of CG400549, a new bacterial enoylacyl carrier protein reductase (Fab1) inhibitor. J. Antimicrob. Chemother. 60, 568-574
14. Park, H. S., Yoon, Y. M., Jung, S. J., Yun, I. N., Kim, C. M., Kim, J. M., and Kwak, J. H. (2007) CG400462, a new bacterial enoyl-Acyl carrier protein reductase (Fab1) inhibitor. Int. J Antimicrob. Agents 30, 446-451
15. Escaich, S., Prouvensier, L., Saccomani, M., Durant, L., Oxoby, M., Gerusz, V., Moreau, F., Vongsouthi, V., Maher, K., Morrissey, I., and Soulama-Mouze, C. (2011) The MUT056399 inhibitor of Fab1 is a new antistaphylococcal compound. Antimicrob. Agents Chemother. 55, 4692-4697
16. Heath, R. J., and Rock, C. O. (2000) A triclosan-resistant bacterial enzyme. Nature 406, 145-146
17. Marrakchi, H., DeWolf, W. E., Jr., Quinn, C., West, J., Polizzi, B. J., So, C. Y., Holmes, D. J., Reed, S. L., Heath, R. J., Payne, D. J., Rock, C. O., and Wallis, N. G. (2003) Characterization of Streptococcus pneumoniae enoyl-[acyl carrier protein] reductase (FabK). Biochem. J. 370, 1055-1062
18. Massengo-Tiassé, R. P., and Cronan, J. E. (2008) Vibrio cholerae fab5 defines a new class of enoyl acyl-carrier-protein reductase. J. Biol. Chem. 283, 1308-1316
19. Chambers, H. F., and Deleo, F. R. (2009) Waves of resistance. Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7, 629-641
20. Walsh, C. (2003) Where will new antibiotics come from? Nat. Rev. Microbiol. 1, 65-70
21. Karlowsky, J. A., Laing, N. M., Baudry, T., Kaplan, N., Vaughan, D., Hoban, D. J., and Zhanel, G. G. (2007) In vitro activity of API-1252, a novel Fab1 inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents. Chemother. 51, 1580-1581
22. Karlowsky, J. A., Kaplan, N., Hafkin, B., Hoban, D. J., and Zhanel, G. G. (2009) AFN-1252, a Fab1 inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob. Agents Chemother. 53, 3544-3548
23. Banevicius, M. A., Kaplan, N., Hafkin, B., and Nicolau, D. P. (2013) Pharmacokinetics, pharmacodynamics and efficacy of novel Fab1 inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J. Chemother. 25, 26-31
24. Kaplan, N., Awrey, D., Bardouniotis, E., Berman, J., Yethon, J., Pauls, H. W., and Hafkin, B. (2013) In vitro activity (MICs and rate of kill) of AFN-1252, a novel Fab1 inhibitor, in the presence of serum and in combination with other antibiotics. J. Chemother. 25, 18-25
25. Kaplan, N., Albert, M., Awrey, D., Bardouniotis, E., Berman, J., Clarke, T., Dorsey, M., Hafkin, B., Ramnauth, J., Romanov, V., Schmid, M. B., Thalakada, R., Yethon, J., and Pauls, H. W. (2012) Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal Fab1 inhibitor. Antimicrob. Agents Chemother. 56, 5865-5874
26. Parsons, J. B., Frank, M. W., Subramanian, C., Saenkham, P., and Rock, C. O. (2011) Metabolic basis for the differential susceptibility of Grampositive pathogens to fatty acid synthesis inhibitors. Proc. Natl. Acad. Sci. U.S.A. 108, 15378-15383
27. Kreiswirth, B. N., Löfdahl, S., Betley, M. J., O'Reilly, M., Schlievert, P. M., Bergdoll, M. S., and Novick, R. P. (1983) The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305, 709-712
28. McAllister, K. A., Peery, R. B., and Zhao, G. (2006) Acyl carrier protein synthases from Gram-negative, Gram-positive, and atypical bacterial species. Biochemical and structural properties and physiological implications. J. Bacteriol. 188, 4737-4748
29. Jackowski, S., and Rock, C. O. (1983) Ratio of active to inactive forms of acyl carrier protein in Escherichia coli. J. Biol. Chem. 258, 15186-15191
30. Bligh, E. G., and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917
31. Morrison, J. F. (1969) Kinetics of the reversible inhibition of enzymecatalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185, 269-286
32. Copeland, R. A. (2005) Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem. Anal. 46, 1-265
33. Ciusa, M. L., Furi, L., Knight, D., Decorosi, F., Fondi, M., Raggi, C., Coelho, J. R., Aragones, L., Moce, L., Visa, P., Freitas, A. T., Baldassarri, L., Fani, R., Viti, C., Orefici, G., Martinez, J. L., Morrissey, I., and Oggioni, M. R. (2012) A novel resistance mechanism to triclosan that suggests horizontal gene transfer and demonstrates a potential selective pressure for reduced biocide susceptibility in clinical strains of Staphylococcus aureus. Int. J. Antimicrob. Agents 40, 210-220
34. Schujman, G. E., Paoletti, L., Grossman, A. D., and de Mendoza, D. (2003) FapR, a bacterial transcription factor involved in global regulation of membrane lipid biosynthesis. Dev. Cell 4, 663-672
35. Schujman, G. E., Altabe, S., and de Mendoza, D. (2008) A malonyl-CoAdependent switch in the bacterial response to a dysfunction of lipid metabolism. Mol. Microbiol. 68, 987-996
36. Massengo-Tiassé, R. P., and Cronan, J. E. (2009) Diversity in enoyl-Acyl carrier protein reductases. Cell Mol. Life Sci. 66, 1507-1517
37. Rafi, S., Novichenok, P., Kolappan, S., Zhang, X., Stratton, C. F., Rawat, R., Kisker, C., Simmerling, C., and Tonge, P. J. (2006) Structure of acyl carrier protein bound to Fab1, the FAS2 enoyl reductase from Escherichia coli. J. Biol. Chem. 281, 39285-39293
38. Heath, R. J., Yu, Y.-T., Shapiro, M. A., Olson, E., and Rock, C. O. (1998) Broad spectrum antimicrobial biocides target the Fab1 component of fatty acid synthesis. J. Biol. Chem. 273, 30316-30320
39. Lu, H., and Tonge, P. J. (2010) Drug-target residence time. Critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 467-474
40. Priyadarshi, A., Kim, E. E., and Hwang, K. Y. (2010) Structural insights into Staphylococcus aureus enoyl-ACP reductase (Fab1), in complex with NADP and triclosan. Proteins 78, 480-486
41. Ward, W. H., Holdgate, G. A., Rowsell, S., McLean, E. G., Pauptit, R. A., Clayton, E., Nichols,W.W., Colls, J. G., Minshull, C. A., Jude, D. A., Mistry, A., Timms, D., Camble, R., Hales, N. J., Britton, C. J., and Taylor, I. W. (1999) Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38, 12514-12525
42. Lee, H. H., Moon, J., and Suh, S. W. (2007) Crystal structure of the Helicobacter pylori enoyl-Acyl carrier protein reductase in complex with hydroxydiphenyl ether compounds, triclosan and diclosan. Proteins 69, 691-694
43. Kim, K. H., Ha, B. H., Kim, S. J., Hong, S. K., Hwang, K. Y., and Kim, E. E. (2011) Crystal structures of enoyl-ACP reductases 1 (Fab1) and 3 (FabL) from B. subtilis. J. Mol. Biol. 406, 403-415
44. Parsons, J. B., Kukula, M., Jackson, P., Pulse, M., Simecka, J. W., Valtierra, D., Weiss, W. J., Kaplan, N., and Rock, C. O. (2013) Perturbation of Staphylococcus aureus gene expression by the enoyl-Acyl carrier protein reductase inhibitor AFN-1252. Antimicrob. Agents Chemother. 57, 2182-2190
45. Fan, F., Yan, K., Wallis, N. G., Reed, S., Moore, T. D., Rittenhouse, S. F., DeWolf, W. E., Jr., Huang, J., McDevitt, D., Miller, W. H., Seefeld, M. A., Newlander, K. A., Jakas, D. R., Head, M. S., and Payne, D. J. (2002) Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 3343-3347
46. Brenwald, N. P., and Fraise, A. P. (2003) Triclosan resistance in methicillin- resistant Staphylococcus aureus (MRSA). J. Hosp. Infect. 55, 141-144
47. Levy, S. B. (2001) Antibacterial household products. Cause for concern. Emerg. Infect. Dis. 7, 512-515